Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBIT (2020 - 2025)

iSpecimen (ISPC) has 6 years of EBIT data on record, last reported at -$2.8 million in Q3 2025.

  • For Q3 2025, EBIT fell 65.96% year-over-year to -$2.8 million; the TTM value through Sep 2025 reached -$12.1 million, down 24.31%, while the annual FY2024 figure was -$12.7 million, 13.96% down from the prior year.
  • EBIT reached -$2.8 million in Q3 2025 per ISPC's latest filing, down from -$1.8 million in the prior quarter.
  • Across five years, EBIT topped out at -$942644.0 in Q1 2021 and bottomed at -$5.8 million in Q4 2024.
  • Average EBIT over 5 years is -$2.4 million, with a median of -$2.2 million recorded in 2023.
  • Peak YoY movement for EBIT: plummeted 150.19% in 2022, then soared 45.4% in 2025.
  • A 5-year view of EBIT shows it stood at -$2.0 million in 2021, then dropped by 7.35% to -$2.1 million in 2022, then crashed by 34.06% to -$2.9 million in 2023, then tumbled by 103.43% to -$5.8 million in 2024, then soared by 51.54% to -$2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$2.8 million in Q3 2025, -$1.8 million in Q2 2025, and -$1.6 million in Q1 2025.